. Author manuscript; available in PMC: 2016 Apr 25.

Published in final edited form as: Curr Oncol Rep. 2012 Aug;14(4):333–341. doi: 10.1007/s11912-012-0240-1

Table 2.

Retrospective case series of patients with oligometastatic NSCLC to the adrenal undergoing adrenalectomy

Study	No. Patients by Presentation			Survival influenced by presentation (S versus M)	Median Survival (months)	5-Year Survival (%)
Study	All	S	M	Survival influenced by presentation (S versus M)	Median Survival (months)	5-Year Survival (%)
Raz, et al. (2011) [55]	20	12	8	No	19	34
Holy, et al. (2011)^* [56]	13				23
Tanvetyanon, et al. (2008)^* [57]	114	48	66	Yes	S: 12M: 31	S: 26M: 25
Mercier, et al. (2005) [58]	23	6	17	No	13	23
Pfannschmidt, et al. (2005) [59]	11	5	6	No	13
Porte, et al. (2001) [60]	43	32	11	No	11	7
Ambrogi, et al. (2001) [61]	5	5	0			60
Beitler, et al. (1998)^* [62]	32	19	13	No	24	33

S denotes patients with a synchronous adrenal metastasis. M denotes patients with a metachronous adrenal metastasis.

Holy, et al. reviewed cases of adrenal metastases treated with SBRT. The studies by Tanvetyanon, et al. and Beitler, et al. were pooled analyses of published case series. The analysis from Tanvetyanon, et al. included the case series from Mercier, et al. and Pfannschmidt, et al.